filings.toolsItem 9B. OTHER INFORMATION
2K characters. Original on sec.gov · Markdown
Item 9B. OTHER INFORMATION
Insider Adoption or Termination of Trading Arrangements:
During the quarter ended December 31, 2024, none of the Company’s directors or officers informed it of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below:
| Name and Title | Date Adopted | Character of Trading Agreement | Aggregate Number of Shares of Common Stock to be (Sold) Purchased Pursuant to Trading Agreement | Duration | |||||||||||||||||||||||||||||||
| Mark S. Schroeder | 11/26/2024 | Rule 10b5-1 Trading Arrangement | Up to | (10,115) | (1) (2) | 11/7/2025 | (3) | ||||||||||||||||||||||||||||
| President, Diagnostics Laboratories and Chief Operations Officer | |||||||||||||||||||||||||||||||||||
| Amy B. Summy | 11/26/2024 | Rule 10b5-1 Trading Arrangement | Up to | (1,234) | (1) | 11/14/2025 | (3) | ||||||||||||||||||||||||||||
| Chief Marketing Officer |
(1)The figure presented represents the shares to be sold on the vesting of equity awards and may vary subject to the achievement of certain performance conditions and/or shares to be withheld for tax purposes.
(2)Mr. Schroeder’s plan provides for the exercise of vested stock options and the associated sale of up to 3,903 shares of the Company’s Common Stock and 76 shares of Common Stock previously acquired from an equity award vesting event.
(3)This trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales on the respective order entry date or (b) the date listed in the table.
Previous: Item 9A. CONTROLS AND PROCEDURES · Next: Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS